posted on 2022-09-26, 20:18authored byJiajun Xu, Tianyang Han, Yajun Wang, Feiran Zhang, Mengfei Li, Lang Bai, Xinyu Wang, Bin Sun, Xin Wang, Jianshi Du, Kun Liu, Junhu Zhang, Shoujun Zhu
The renal-clearable aspect of imaging agent with minimum
toxicity
issues and side effects is essential for clinical translation, yet
clinical near-infrared-I/II (NIR-I/II) fluorophores with timely renal-clearance
pathways are very limited. Herein, we rationally develop the cyanine-protein
composite strategy through covalent bonding of β-lactoglobulin
(β-LG) and chloride-cyanine dye to produce a brilliant and stable
NIR-I/II fluorophore (e.g., β-LG@IR-780). The β-LG acts
as a protecting shell with small molecular weight (18.4 kDa) and ultrasmall
size (<5 nm), thus endowing the β-LG@IR-780 with excellent
biocompatibility and renal excretion. Our β-LG@IR-780 probe
enables noninvasive and precise NIR-II visualization of the physiological
and pathological conditions of the vascular and lymphatic drainage
system, facilitating intraoperative imaging-guided surgery and postoperative
noninvasive monitoring. The minimum accumulation of our probes in
the main organs improves the overall biosafety. This study provides
a facile methodology for new-generation NIR-II fluorophores and largely
improves the brightness and pharmacokinetics of small molecular dyes.